Tg Therapeutics (TGTX) Current Deferred Revenue (2012 - 2026)

Tg Therapeutics' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $17.2 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 0.65% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $17.2 million (up 0.65% YoY), while the FY2025 annual figure was $21.2 million, up 86.03% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $17.2 million, down from $21.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $26.4 million in Q3 2025, with the low at $152000.0 in Q4 2023.
• The 5-year median for Current Deferred Revenue is $3.4 million (2024), against an average of $8.4 million.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue sank 69.6% in 2023, then surged 7409.21% in 2024.
• Tg Therapeutics' Current Deferred Revenue stood at $500000.0 in 2022, then tumbled by 69.6% to $152000.0 in 2023, then soared by 7409.21% to $11.4 million in 2024, then jumped by 86.03% to $21.2 million in 2025, then fell by 19.04% to $17.2 million in 2026.
• Business Quant data shows TGTX's Current Deferred Revenue at $17.2 million in Q1 2026, $21.2 million in Q4 2025, and $26.4 million in Q3 2025.